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Each month, the American Journal of Transplantation will feature Images in Transplantation, a journal-based CME activity, chosen to educate 
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Statement of Need
BK virus nephropathy (BKVN) is a signifi cant cause of allograft dysfunction post–kidney transplant. Due to the similarities with acute rejection, 
BKVN may be misinterpreted as acute rejection. It is important to distinguish between the two since treatment for presumed rejection with increased 
immunosuppression may result in allograft loss.
Purpose of Activity
The activity is designed to improve the physician’s knowledge about challenges in diagnosis of BKVN.
Identifi cation of Practice Gap
Many transplant providers may lack experience in diagnosing, treating and distinguishing BKVN from acute rejection. Correct diagnosis of BKVN 
enhances kidney allograft survival. 
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Upon completion of this educational activity, participants will be able to:
•  Recognize pitfalls in the diagnosis of BKVN.
•  Differentiate BKVN from acute rejection.
•  Understand appropriate treatment strategy for BKVN.
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Instructions on Receiving CME Credit
This activity is designed to be completed within an hour. Physicians should claim only those credits that refl ect the time actually spent in the activity. 
This activity will be available for CME credit for twelve months following its publication date. At that time, it will be reviewed and potentially 
updated and extended for an additional twelve months.
Follow these steps to participate, answer the questions and claim your CME credit:
• Log on to https://www.wileyhealthlearning.com/ajt
• Read the learning objectives, target audience, and activity disclosures.
• Read the article in print or online format.
• Refl ect on the article.
• Access the CME Exam, and choose the best answer to each question.
• Complete the required evaluation and print your CME certifi cate.
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Renal Failure in a Kidney Transplant Recipient—BK 
Virus Nephropathy or Rejection?
A 53-year-old Hispanic female received a deceased-donor kidney transplant. Posttransplant, she achieved a baseline 
serum creatinine of 1.2–1.4 mg/dL. Her maintenance immunosuppression consisted of mycophenolate mofetil 720 mg 
twice daily, tacrolimus 6 mg twice daily and prednisone 5 mg daily. One-and-a-half years posttransplantation, patient was 
diagnosed with biopsy-proven BK virus nephropathy (BKVN) with a serum BK virus polymerase chain reaction (PCR) 
of 135,000 copies/mL. The immunosuppression was reduced (tacrolimus 3 mg twice daily and mycophenolate 360 mg 
twice daily). Subsequently serum creatinine improved to a baseline of 1.5–1.7 mg/dL and serum BK viremia became 
undetectable over the next year. She was continued on the lower immunosuppression, and 3 years posttransplantation, 
patient was admitted with serum creatinine of 2.5 mg/dL. Serum John Cunningham (JC) virus PCR was negative and 
BK virus PCR was undetectable at <5000 copies/mL. Donor-specifi c HLA antibodies were negative. The transplant 
kidney biopsy showed moderate interstitial fi brosis/tubular atrophy with infl ammation (Figure 1), focal tubulitis (star, 
Figure 2) with tubular cells showing slightly enlarged and hyperchromatic nuclei (arrow, Figure 2). No viral cytopathic 
effects were identifi ed. The stain for polyomavirus showed weak (1+) nuclear staining (Figure 3). The C4d stain was 
negative. Acute cellular rejection Banff 1B was diagnosed and patient was treated with high-dose intravenous steroids 
with improvement in serum creatinine to nadir of 1.8 mg/dL a week later. Subsequently, serum creatinine increased to 
3.0 mg/dL a month later. A second transplant biopsy showed persistent infl ammation with stronger polyomavirus staining 
compared to previous biopsy. Serum BK virus PCR was now detectable at 6800 copies/mL.
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Figure 1: The hematoxylin and eosin stain of transplant kidney 
biopsy done 3 years posttransplantation reveals moderate 
interstitial fi brosis and tubular atrophy with infl ammatory 
infi ltration. Serum creatinine was 2.5mg/dL and serum BK virus PCR 
was undetectable at <5000 copies/mL on the day of biopsy.
Figure 2: The hematoxylin and eosin stain of transplant kidney 
biopsy done 3 years posttransplantation shows area of tubulitis (star) 
and a tubular epithelial cell with an enlarged and hyperchromatic 
nuclei (arrow). No viral cytopathic effects were seen. 
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Questions
1. Which of the following statements is true about diagnosis of BKVN?
a. The absence of viral cytopathic effects in the transplant kidney biopsy (Figure 2) rules out a diagnosis of BKVN.
b. The BK virus inclusion bodies are characteristically present in the cell cytoplasm. 
c. The onset of serum BK viremia usually coincides with the diagnosis of BKVN.
d.  The positive and negative predictive value of BK virus PCR for diagnosis of BKVN is reported to be 60% and 100% respectively.
e. The detection of immunoglobulin-M (IgM) and the degree of rise of IgM levels may help in diagnosis of BKVN.
2. The biopsy confi rmed polyomavirus nephropathy (PyVAN) may be seen in the absence of detectable serum BK viremia in all of the 
following conditions except:
a. JC virus nephropathy
b. Absence of BK virus–specifi c T cells
c. Residual BKVN posttreatment 
d. Inter-laboratory variation in BK virus quantifi cation
e. BK virus genotype variance
3. Which of the following tests may best help distinguish BKVN from acute cellular rejection?
a. Urinary mRNA for BKV-VP1 
b. Urinary mRNA for granzyme B 
c. Urinary interferon-gamma (IFN-)-inducible protein-10
d. Urine decoy cells
e. Plasma cell rich infl ammation and increased HLA-DR expression on kidney biopsy
4. The most commonly accepted strategy for treatment of PyVAN is:
a. Reduction in immunosuppression
b. Lefl unomide
c. Cidofovir
d. Ciprofl oxacin
e. Intravenous immunoglobulin
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Figure 3: The immu nohistochemistry of transplant kidney biopsy done 
3 years posttransplantation shows a few tubular cells with weak (1+) stain 
for polyomavirus.
